Orangecat, I don't believe Fresenius has left the countries in Europe in exchange for South Korea and Mexico. Doesn't the latest agreement simply allow for the expansion of Cytosorb into these previously exclusive areas? Dr Chan did a good job in the question and answer period explaining the effectivness of the sales personnel from Cytosorb over the sales force of Fresenius because the filter is our only product verses many products that the Fresenius sales force deals with. Fresenius will work down the inventory they have. This change may have come about because of the improvement of the sales numbers when compared between Fresenius sales efforts and ours. On another note, as I listen to the presentations by Dr. Chan, I get the feeling that Dr. Chan is trying to stuff as much detailed information as he possibly can into a fixed amount of time. At times during the presentation he almost sounds like an auctioneer, and I could hear him struggling with the mechanics of all the words he wants to say in the limited amount of time to say it. He could improve the flow of the presentation and give himself the benefit of relaxing a bit more if he didn't try to fill in all the technical aspects to such detail for all the applications he presents. The physics of the filter and its action, yes, but all the details, maybe not. There are many people listening to him who's interests might be picked allowing for a productive question and answer period following the presentation. Establishing that one on one within a group is very important for a successful sales presentation and subsequent Q and A's, and I'm sure it is a challenge to do so while following the guidelines of safe harbor and the make up of different groups, ie., investor confrences vs Cytosorb Users Meetings... it is a challenge. That being said, it is also good to see Cytosorbents acceleration of acceptance of this science.
News 
Market Data 
Discover 
